Single-Dose HPV Vaccination Among Young Adult Women in Costa Rica: the PRISMA-ESCUDDO Trial (PRevencIón Del Cáncer Cervical Con Una Sola Dosis de Vacuna Contra VPH en Mujeres Adultas Jóvenes)

This phase IV trial tests whether a single dose of the human papillomavirus (HPV) vaccine works in preventing cervical cancer in young women in Costa Rica. Human papilloma viruses, called HPV, are a group of viruses that very frequently cause infection in both men and women, mainly in the genital organs. There are many types of HPV, and some can cause cancer. The World Health Organization recommends a two-dose schedule for adolescents 9-14 and three doses for individuals 15 years old or older. This study examines whether a single dose of HPV vaccine can reduce the frequency with which women between ages 18-30 become infected with HPV.

Start Date01 Mar 2022

Sponsor / Collaborator

National Cancer Institute

NCT04301154

/ Active, not recruitingPhase 1IIT

Phase I, Proof of Concept, Open-Label, Randomized Clinical Trial to Evaluate the Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth

Phase I, Proof of Concept, Open-Label, Randomized Clinical Trial to Evaluate the Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens with or without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth

Start Date18 Feb 2022

Sponsor / Collaborator

The Henry M. Jackson Foundation

[+11]

CTR20210523

/ CompletedPhase 4

一项监测葛兰素史克生物制品公司希瑞适疫苗上市前后依据当地处方信息接种希瑞适疫苗的9-45岁中国女性安全性相关终点的观察性数据库研究。

[Translation] An observational database study monitoring safety-related endpoints in Chinese women aged 9-45 years who received GlaxoSmithKline Biologicals' Cervarix vaccine according to local prescribing information before and after its launch.

第1步：评估数据库中识别安全性相关终点的性能（次要目的）：针对所关注的潜在免疫介导疾病（pIMD）和妊娠结局，评估病例识别方法的准确性。第2步：基线分析（次要目的）：估算上市前观察期9~45岁女性pIMD发病率，包括每个日历年的总体与年龄别发病率。估算上市前观察期9~45岁怀孕女性中妊娠结局发病率，包括每个日历年的总体与年龄别发病率。估算9~45岁女性希瑞适疫苗接种率，包括每个日历年的总体与年龄别接种率。第3步：主要分析（主要目的）：估算上市前和上市后观察期间，9~45岁女性可识别的最常见的pIMD的发病率，包括每个日历年的总体与年龄别发病率。估算上前和上市后观察期间9~45岁妊娠女性中可识别的妊娠结局的发病率，包括每个日历年的总体与年龄别发病率。第4步：条件性分析（次要目的）：以疫苗接种率和实际观察的发病率为前提条件，评估上市前、后在接种和未接种希瑞适疫苗的人群中，疫苗接种后12个月内发生可识别的最常见的pIMD的可能性。以疫苗接种率和实际观察的发病率为前提条件，评估上市前、后在接种和未接种希瑞适疫苗的人群中，疫苗接种后发生可识别的妊娠结局的可能性。

[Translation]

Step 1: Evaluate the performance of identifying safety-related endpoints in the database (secondary objective): Evaluate the accuracy of the case identification method for potential immune-mediated diseases (pIMDs) and pregnancy outcomes of interest. Step 2: Baseline analysis (secondary objective): Estimate the incidence of pIMDs in women aged 9 to 45 years during the pre-marketing observation period, including overall and age-specific incidence rates for each calendar year. Estimate the incidence of pregnancy outcomes in pregnant women aged 9 to 45 years during the pre-marketing observation period, including overall and age-specific incidence rates for each calendar year. Estimate the vaccination rate of Cervarix in women aged 9 to 45 years, including overall and age-specific vaccination rates for each calendar year. Step 3: Primary analysis (primary objective): Estimate the incidence of the most common pIMDs that can be identified in women aged 9 to 45 years during the pre-marketing and post-marketing observation periods, including overall and age-specific incidence rates for each calendar year. Estimate the incidence of identifiable pregnancy outcomes in pregnant women aged 9 to 45 years during the pre-marketing and post-marketing observation periods, including overall and age-specific incidence rates for each calendar year. Step 4: Conditional analysis (secondary objective): To assess the likelihood of identifiable pregnancy outcomes occurring within 12 months after vaccination in the pre- and post-marketing population with and without Cervarix, conditioned on vaccination coverage and observed incidence. To assess the likelihood of identifiable pregnancy outcomes occurring within 12 months after vaccination in the pre- and post-marketing population with and without Cervarix, conditioned on vaccination coverage and observed incidence.

Start Date10 Sep 2021

Sponsor / Collaborator

GlaxoSmithKline (China) Investment Co., Ltd.

[+1]

100 Clinical Results associated with Human papillomavirus vaccine [types 16, 18](GlaxoSmithKline Plc)

100 Translational Medicine associated with Human papillomavirus vaccine [types 16, 18](GlaxoSmithKline Plc)

100 Patents (Medical) associated with Human papillomavirus vaccine [types 16, 18](GlaxoSmithKline Plc)

365

Literatures (Medical) associated with Human papillomavirus vaccine [types 16, 18](GlaxoSmithKline Plc)

31 Dec 2024·Human Vaccines & Immunotherapeutics

Effectiveness of HPV vaccine as part of national immunization program for preventing HPV infection in Thai schoolgirls after seven years post-vaccination

Article

Author: Wanlapakorn, Nasamon ; Nilyanimit, Pornjarim ; Aeemchinda, Ratchadawan ; Poovorawan, Yong ; Suntronwong, Nungruthai ; Seetho, Sunanta ; Netthip, Naiyana ; Bhunyakitikorn, Wichan ; Phosri, Darunee ; Thantithaveewat, Thanawadee ; Vichaiwattana, Preeyaporn

Thailand introduced a two-dose regimen of bivalent HPV vaccines for Grade 5 schoolgirls, approximately 11 years old, initially piloted in Ayutthaya province in 2014, and nationwide under the National Immunization Program (NIP) in 2017. This cross-sectional, case-control study evaluated the vaccine effectiveness in schoolgirls 7 years after a two-dose administration. Between May and June 2023, 211 grade 12 female students from Ayutthaya, who received the two-dose bivalent HPV vaccine CERVARIX^Ⓡ (HPV types 16 and 18), and 376 grade 12 students from Nakhon Pathom who did not receive the HPV vaccine, were enrolled. HPV infection was detected by testing for HPV DNA in the first-void urine samples using real-time PCR (Cobas® 4800 and Anyplex^TM HPV28). The study found that the HPV vaccine 100% effective against high-risk HPV (HR-HPV) types included in the vaccine (16, 18) and 32.8% effective against other HR-HPV types not included in the vaccine. Our findings indicated that the bivalent HPV vaccine does not provide cross-protection against non-vaccine HPV types. Prioritizing vaccines with the highest coverage of HR-HPV types, such as the nonavalent HPV vaccine, is crucial to effectively prevent a broader range of HR-HPV infections under the NIP.

10 Nov 2024·West African journal of medicine

KNOWLEDGE AND PERCEPTION OF HUMAN PAPILLOMAVIRUS VACCINE AMONG ADOLESCENTS AND CAREGIVERS IN JOS METROPOLIS, PLATEAU STATE, NIGERIA.

Article

Author: Tony-Okeke, T O ; Aule, S K ; Mathew, M ; Odoh, A F ; Zoakah, J H ; Nnorom, O C ; Envuladu, E A

Introduction:

HPV infection is well-recognized as a cause of nearly all cases of cervical cancer. There are currently three prophylactic HPV vaccines; a bivalent (Cervarix), a quadrivalent (Gardasil), and a nonavalent vaccine (Gardasil- 9). With the recent rollout of HPV vaccines in Nigeria, it is imperative to understand potential barriers and facilitators to its uptake.

Objectives:

The objectives of this study were to evaluate the awareness, perception, and willingness to accept HPV vaccine and explore enablers and barriers to HPV vaccine uptake among adolescents and caregivers.

Methods:

Four focus group discussions were conducted with adolescents from public and private secondary schools in Plateau, 4 with the parents of adolescents, and one IDI with the head of ANCOPSS. Each FGD had between 8-12 participants. Interviews were recorded and notes were taken. The interviews were transcribed, codes were generated and analysis was conducted using a thematic framework approach with NVIVO version 11 software.

Results:

Most participants demonstrated inadequate knowledge and poor perception of HPV and the vaccine. Girls were willing to accept the vaccine, while boys saw it as a female problem. Parents had limited knowledge but expressed willingness to allow their children to be vaccinated. The fear of side effects, poor vaccine quality, and lack of parental approval were major barriers expressed by the girls while myths and misconceptions regarding the vaccine interference with fertility and as a means of population control were significant barriers on the parts of the parents.

Conclusion:

Low awareness and poor perception of HPV vaccine exist among adolescents and caregivers. Long-term individual and community-level interventions are needed to provide accurate information address knowledge gaps and promote inclusive access.

01 Oct 2024·VACCINE

How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects?

Article

Author: Navarro-Torné, Adoración ; Checchi, Marta ; Anderson, Anja ; Beddows, Simon ; Ghys, Emmanuelle ; Panwar, Kavita ; Weynants, Vincent ; Benninghoff, Bernd

BACKGROUND:

Bivalent human papillomavirus HPV16/18-AS04 vaccine (Cervarix, GSK) offers direct protection against HPV16/18. Results from randomised controlled trials showed cross protective effects and suggested that declines in some closely related HPV types could be expected in a population with high vaccination coverage.

AIM:

To evaluate the evidence for cross-protection afforded by HPV16/18-AS04 from post-implementation surveillance in England, and how this complements clinical trial data and post-implementation observations in other countries.

METHODS:

Evidence of cross-protection in young women offered vaccination with HPV16/18-AS04 was gathered from HPV surveillance in England. Data from clinical trials and other post-implementation studies were reviewed.

RESULTS:

Surveillance using anonymised residual specimens in England found declines of 52.3%, 67.4% and 33.3% against grouped HPV-31/33/45 in 16-18, 19-21, and 22-24 year olds, respectively. Additionally, type-specific analysis found that the prevalence of HPV31 declined to below 1% across all age groups. Cross-protection has been monitored and maintained for over 10 years since the introduction of the vaccination programme. Cross-protection against HPV6/11 was not found in English surveillance outcomes.

CONCLUSION:

Surveillance of type-specific infections in vaccine-eligible populations in England has generated clear evidence of cross-protective effects from HPV16/18-AS04 vaccination against high-risk HPV 31/33/45 infections, consistent with other post-implementation observations and confirming and in some ways exceeding expectations from clinical trials.

News (Medical) associated with Human papillomavirus vaccine [types 16, 18](GlaxoSmithKline Plc)

02 Dec 2024

·www.drugs.com

Cervical Cancer Deaths Fell Dramatically After Advent of HPV Vaccine

MONDAY, Dec. 2, 2024 -- A new study provides good evidence that the human papillomavirus (HPV) vaccine may be achieving its goal of slashing rates of cervical cancer. “We observed a … 62% drop in cervical cancer deaths over the last decade, likely due to HPV vaccination,” said study senior author Ashish Deshmukh . “We cannot think of any other reason that would have contributed to such a marked decline.” Deshmukh is co-leader of the Cancer Prevention and Control Research Program at the Medical University of South Carolina's Hollings Cancer Center. HPV, a common sexually transmitted infection, is thought to cause the vast majority of cervical cancer cases. First introduced and approved in the United States in 2006, HPV vaccines such as Gardasi l and Cervarix have revolutionized cervical cancer prevention and care. It takes time to see vaccination translated into real world outcomes, such as a decline in cancer deaths. But studies focused on earlier markers -- HPV infection, precancer and new cases of cervical cancer -- had suggested that widespread vaccination among adolescents and young women might be having an impact. The new study tracked U.S. deaths among women under the age of 25 from the beginning of the 1990s through 2021. Such deaths at a very young age are rare, but Deshmukh and colleagues said that tracking them is a good indicator of whether vaccines might be working. They pointed out that in 2021, women who were 25 would have been 10 years old in 2006, when the vaccine was first introduced. The U.S. Centers for Disease Control and Prevention recommends that HPV vaccines be given to adolescents at ages 11 to 12, before the typical start of sexual activity. The team found that between 50 and 60 women under the age of 25 died of cervical cancer during every three-year block of time throughout the 1990s. However, between 2019 and 2021, that rate had fallen by nearly two-thirds, to 13 deaths over those three years. Of course, girls and women can only be protected by the HPV vaccine if they are immunized, Deshmukh said. The CDC has set a goal of an 80% vaccination rate, but its data for 2024 show that only about 60% of 13-to -15-year-olds have received the recommended doses. “There has been a decline in HPV vaccination post COVID-19 in the most recent generation of U.S. adolescent," Deshmukh said in a university news release. "This is troubling, as a decline in vaccination uptake would potentially lead to smaller gains [against cervical cancer]." The findings were published Nov. 27 in the Journal of the American Medical Association. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

VaccineDrug Approval

21 Nov 2024

·vicebio.com

Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine…

Vicebio enters the second stage of its Phase 1 Clinical Study of its lead candidate VXB-241 The Clinical Study, an actively controlled Proof of Concept Phase 1 conducted in target population aged 60+, is progressing as planned with initial data expected by mid-2025 Moncef Slaoui, former Chief Scientific Advisor of Operation Warp Speed & former Chair of R&D at GlaxoSmithKline and Khurem Farooq, previously CEO of Aiolos, join Board of Directors London, UK, 21 November 2024: Vicebio Ltd (“Vicebio”), a biopharmaceutical company pioneering next-generation vaccines for life-threatening respiratory viruses, today announces its progress in the ongoing VXB-241 bivalent RSV-hMPV Phase 1 (P1) study as well as the appointment of Moncef Slaoui, PhD, and Khurem Farooq to its Board of Directors. Vicebio is progressing into the second stage of its clinical study of VXB-241 and is now enrolling individuals aged 60 years of age and above to evaluate the candidate vaccine’s safety in this vulnerable population. Early data from the study are expected by mid-2025. Vicebio anticipates these data will represent a significant milestone in the clinical validation of its platform. More information on the P1 study can be found on clinicaltrials.gov (NCT06556147). Moncef Slaoui, PhD, and Khurem Farooq join the Board of Directors, effective immediately. Both bring vast experience in vaccine development and biopharmaceutical leadership. Emmanuel Hanon, Chief Executive Officer of Vicebio, said: “In connection with our significant Series B financing, we are building upon our world-class leadership team with the addition of Moncef and Khurem to the Board. Their expertise not only further supports our innovation but will be essential as we continue to advance the Company’s vision to deliver the next generation of respiratory viral vaccines.” At the heart of Vicebio’s innovation is its proprietary Molecular Clamp technology, designed to stabilise viral antigens and enhance protective immunity across multiple respiratory pathogens. This transformative technology supports the development of multivalent respiratory viral vaccines that are ready-to-use, cost-effective, and capable of addressing critical needs in global respiratory health. Moncef Slaoui, PhD, newly appointed Independent Board Member at Vicebio, commented: “Vicebio’s Molecular Clamp technology marks a transformative advancement in vaccine development. It is fantastic to be joining the Board of a company where the technology and novel approach holds the potential to expedite delivery of highly effective and stable vaccines in ready-to-use prefilled syringes.” Khurem Farooq, newly appointed Independent Board Member at Vicebio, added: “Vicebio is at an exciting phase of growth as it looks to advance its pipeline of multivalent vaccines with the potential to prevent a wide range of diseases in a single vaccine.” Moncef Slaoui, PhD, has extensive experience in drug development and commercialisation. He currently serves as an advisor to Medicxi and is on the Board of Directors of several companies including Arcturus Therapeutics, Altesa, and Zephyr AI. Under his leadership as Chief Scientific Advisor to Operation Warp Speed, he played a critical role in the rapid development and deployment of multiple of COVID-19 vaccines in the US. Prior to this Moncef’s career at GlaxoSmithKline (GSK) spanned nearly three decades, where he held several senior leadership roles, including being a member of the Board of Directors. He spearheaded GSK’s Pharmaceutical R&D restructuring to improve focus on innovation and productivity, and was instrumental in the development of 14 new vaccines, including Shingrix, to prevent shingles; Cervarix, to prevent cervical cancer and Mosquirix, to prevent malaria. Moncef earned a PhD in Molecular Biology and Immunology from the Université Libre de Bruxelles and completed postdoctoral studies at Harvard Medical School and Tufts University. He also holds an accelerated MBA from IMD in Switzerland. Khurem Farooq is an avid biotech entrepreneur with over 20 years of experience in drug development. Khurem was co-founder and CEO of Aiolos Bio, which was acquired by GSK for $1.4bn in February 2024. Prior to this, Khurem served as CEO of Gyroscope, which was acquired by Novartis in 2021 for up to $1.5bn. Khurem was Senior Vice President of the Immunology and Ophthalmology business unit at Genentech, a member of the Roche Group, where he played a key role in the commercialisation and launch strategies of several medicines and contributed to the development of numerous pipeline products. He holds an MBA and a BSc in Biological Sciences, with honours, from Aston University and University of Wolverhampton, respectively. For further information, please contact: Optimum Strategic Communications Mary Clark, Hana Malik, Vareen Outhonesack Tel: +44 (0) 203 922 0889 Email: vicebio@optimumcomms.com Vicebio is backed by a global syndicate of life science investors including Medicxi, UniQuest, TCGX, Goldman Sachs Alternatives, Avoro Ventures and venBio. For more information, please visit: www.vicebio.com About Vicebio Vicebio is focused on developing next-generation respiratory virus vaccines using the Molecular Clamp Technology. The company was founded with investment from Medicxi and acquired the rights to the Molecular Clamp technology through a license from UniQuest, the commercialization arm of The University of Queensland, Australia. This proprietary technology was developed by Prof. Paul Young, Prof. Daniel Watterson, and Prof. Keith Chappell at UQ. For more information, please visit: https://www.vicebio.com About Medicxi Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full drug development continuum. Leveraging deep expertise in drug development and company creation spanning over two decades, Medicxi invests in early and late-stage therapeutics with a product vision that can fulfil a clear unmet medical need. For more information, please visit: https://www.medicxi.com About UniQuest UniQuest is the commercialisation company of The University of Queensland (UQ). In partnership with UQ researchers, UniQuest creates impact through the commercialisation of UQ intellectual property. Established in 1984, UniQuest’s commercialisation track record positions UQ as the leader of research commercialisation in Australasia. Notable successes include the blockbuster cervical cancer vaccine Gardasil® and start-up companies Spinifex Pharmaceuticals Inc and Inflazome Ltd, which were acquired in two of the largest university start-ups exits in Australian history. UniQuest has also established the Queensland Emory Drug Discovery Initiative (QEDDI), a world-class small molecule drug discovery and development group, dedicated to translating academic biomedical research into drug candidates for partnering. In 2024, UniQuest launched its AUD$32 million UniQuest Extension Fund, an investment fund dedicated to supporting the start-up eco-system at The University of Queensland. For more information, please visit: https://uniquest.com.au/about/ About TCGX TCGX is a healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that can improve the lives of patients. TCGX invests in pioneering healthcare companies led by exceptional entrepreneurs focused on developing better treatment options for patients. TCGX has investment teams in San Francisco, Palo Alto, and New York City. For more information, please visit: www.tcgcrossover.com Goldman Sachs (NYSE: GS) is one of the leading investors in alternatives globally, with over $450 billion in assets and more than 30 years of experience. The business invests in the full spectrum of alternatives including private equity, growth equity, life sciences, private credit, real estate, infrastructure, hedge funds, and sustainability. Clients access these solutions through direct strategies, customized partnerships, and open-architecture programs. The business is driven by a focus on partnership and shared success with its clients, seeking to deliver long-term investment performance drawing on its global network and deep expertise across industries and markets. The alternative investments platform is part of Goldman Sachs Asset Management, which delivers investment and advisory services across public and private markets for the world’s leading institutions, financial advisors, and individuals. Goldman Sachs has over $2.8 trillion in assets under supervision globally as of March 31, 2024. About Avoro Ventures Avoro Ventures is a global life sciences investment firm, and an affiliated company of Avoro Capital Advisors, an SEC-registered investment manager based in New York City, with over $6.5 billion in capital primarily focused on supporting emerging life sciences and biotechnology companies. For more information, please visit: www.avorocapital.com About venBio venBio is a life sciences investment firm that partners with industry leaders to build innovative medicines and technologies, with a focus on novel therapeutics for unmet medical needs. For more information, please visit: www.venbio.com

VaccinePhase 1AcquisitionExecutive Change

31 Jul 2024

·www.fiercebiotech.com

GSK drops phase 2 HPV vaccine over lack of best-in-class potential

GSK CEO Emma Walmsley told Fierce Biotech that the company is still “keeping an eye on the opportunity in HPV.” GSK has scrapped a phase 2 human papillomavirus (HPV) vaccine from its pipeline after deciding the asset wouldn’t have best-in-class potential.The British Big Pharma—which still markets the HPV vaccine Cervarix in various countries—announced the decision to remove an adjuvanted recombinant protein vaccine for the viral infection, dubbed GSK4106647, from its phase 2 pipeline as part of second-quarter earnings results (PDF).On a call with journalists this morning, CEO Emma Walmsley told Fierce Biotech that while GSK is still “keeping an eye on the opportunity in HPV, for sure,” the company has decided it doesn’t want to pursue GSK4106647 further.“One of the most important things you can do when developing a pipeline is focus on the big bets of new and differentiated assets,” Walmsley said. “And part of that means switching off things where we don't think we can necessarily cut through with something that can be a best in class.”When it comes to GSK’s vaccines portfolio more generally, the company is “doubling down both on mRNA and on our new MAPS technology,” the CEO added. Earlier this month, the Big Pharma paid CureVac $430 million for the full rights to the mRNA specialist’s flu and COVID vaccines. “The key point is: Can you bring something that's new and different and better, where there's material unmet need, and we can demonstrate differentiated value,” she added.GSK still markets the recombinant HPV vaccine Cervarix in various countries around the world. Despite pulling the vaccine from the U.S. in 2016 due to low demand, the company still saw £120 million ($154 million) in global revenue for the shot in 2023.One other drug was removed from GSK’s pipeline this morning: a proteasome inhibitor for a tropical disease called visceral leishmaniasis. Walmsley stressed on the same call that GSK has a “long-term commitment to neglected tropical diseases,” but said the decision to end work on this specific asset was a result of “the discipline of betting where we can win.”

VaccinePhase 2Clinical ResultmRNA

100 Deals associated with Human papillomavirus vaccine [types 16, 18](GlaxoSmithKline Plc)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BM02	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cervical Adenocarcinoma In Situ	US	GlaxoSmithKline LLC	16 Oct 2009
Uterine Cervical Cancer	US	GlaxoSmithKline LLC	16 Oct 2009
Uterine Cervical Cancer	JP	GlaxoSmithKline KK	16 Oct 2009
Uterine Cervical Dysplasia	US	GlaxoSmithKline LLC	16 Oct 2009
Anus Neoplasms	EU	GlaxoSmithKline Biologicals SA	20 Sep 2007
Anus Neoplasms	IS	GlaxoSmithKline Biologicals SA	20 Sep 2007
Anus Neoplasms	LI	GlaxoSmithKline Biologicals SA	20 Sep 2007
Anus Neoplasms	NO	GlaxoSmithKline Biologicals SA	20 Sep 2007
Human Papillomavirus Infection	AU	Glaxosmithkline Australia Pty Ltd.	18 May 2007
Human Papillomavirus-Related Cervical Carcinoma	AU	Glaxosmithkline Australia Pty Ltd.	18 May 2007

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adenocarcinoma in Situ	Phase 3	CN	GlaxoSmithKline (China) Investment Co., Ltd.	28 Feb 2018
Adenocarcinoma in Situ	Phase 3	CN	GlaxoSmithKline Biologicals SA	28 Feb 2018
Meningococcal Infections	Phase 3	DO	GSK Plc	11 Jan 2013
Meningococcal Infections	Phase 3	EE	GSK Plc	11 Jan 2013
Meningococcal Infections	Phase 3	TH	GSK Plc	11 Jan 2013
Chronic human papillomavirus (HPV) infection	Phase 3	SN	GSK Plc	01 Oct 2007
Chronic human papillomavirus (HPV) infection	Phase 3	TZ	GSK Plc	01 Oct 2007
Cervical Intraepithelial Neoplasia	Phase 3	US	GSK Plc	06 May 2004
Cervical Intraepithelial Neoplasia	Phase 3	AU	GSK Plc	06 May 2004
Cervical Intraepithelial Neoplasia	Phase 3	BE	GSK Plc	06 May 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03629886 (HPV-092, CTgov)	Phase 4	Cervical Intraepithelial Neoplasia	6,051	HPV (Types 16, 18) Vaccine, Adsorbed (Vacc-092 Group)	xlcpgqbnyu(txwaatzcns) = ykgctnsqyq tjeefqggkf (gysumbytvw, zmncnzanhh - axyymchmnj) View more	-	19 Dec 2020
				HPV vaccine (Vacc-039 Group)	jwiwokmijw(qmpxtiotck) = tcnrbfbydh uryllbvvcw (vjqzuoqglm, tvzwswpiuw - pbftqozzyt) View more
NCT00231413 (CTgov)	Phase 2	Human Papillomavirus Infection	383	HPV 16/18 L1 AS04 (HPV-16/18 Group)	bqsqacumma(sfkbkpwsjf) = wzofixzseo klpybjplxb (rvowkwmamc, jqfdwpskav - uepukbohvs) View more	-	12 Dec 2019
				HPV-16/18/31/45 L1 AS04 Formulation 1 (HPV-TETRA A Group)	bqsqacumma(sfkbkpwsjf) = wdrwwzkleu klpybjplxb (rvowkwmamc, somiqykkft - htwnhfruim) View more
NCT01031069 (CTgov)	Phase 4	Human Papillomavirus Infection \| HIV Infections	873	GSK Biologicals' HPV vaccine 580299 (HIV+/Cervarix Group)	gdowyvubhe(xasxjbqscq) = qmqvohviah jkvpkjvbgb (wzdtorfhrx, jaydxynixe - pgmulnknnl) View more	-	24 Jul 2019
				Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, (HIV+/Gardasil Group)	gdowyvubhe(xasxjbqscq) = xcvsjuiiao jkvpkjvbgb (wzdtorfhrx, wtbzqvxzpw - jnbngrnsde) View more
NCT01190189 (CTgov)	Phase 3	Human Papillomavirus Infection	137	GSK580299 (Cervarix)	cavjtteoxq(lunrqodntj) = tujcvfkecs aoqflwotvu (wsdyajevus, hbjqomipti - vdhjqljkqj) View more	-	17 Dec 2018
NCT01190176 (CTgov)	Phase 3	Human Papillomavirus Infection	34	Placebo control+Cervarix	nwhztyybis(elsnethrzj) = vdywaqcyoz bzevvwyrxy (kffbfazxgu, xenmhqzaan - hbafpgtlkl) View more	-	17 Oct 2018
NCT01249365 (CTgov)	Phase 3	Human Papillomavirus Infection	199	GSK580299 (Cervarix)	zysgnboxro(wwyfmilfkc) = papbupobwl kpmlvprkyi (jzinyyxtun, zolynkbuov - jspiayfeel) View more	-	16 Jul 2018
NCT01755689 (CTgov)	Phase 3	Meningococcal Infections	1,300	Cervarix®+Meningococcal vaccine GSK134612 (Nimenrix+Cervarix (1,2,7-Month) Group)	pegupuackx(keuqdjgaxx) = imwzijykwh asdvhnszgr (qwcfzavqrs, gnwvcvhnoc - bdyzmexyld) View more	-	03 Jul 2018
				Cervarix®+Meningococcal vaccine GSK134612 (Nimenrix+Cervarix (0,1,6-Month) Group)	pegupuackx(keuqdjgaxx) = eixsewkmro asdvhnszgr (qwcfzavqrs, ckaypznjzy - thspgzbgme) View more
NCT01101542 (Pubmed \| Pharmacoepidemiol Drug Saf)	Not Applicable	Human Papillomavirus Infection \| Uterine Cervical Cancer	3,084	HPV-16/18 AS04-adjuvanted vaccine	fengmgnuid(dgcnnruitl) = Dysmenorrhoea was the most common unexpected AE reported by 30 subjects (1.0% [95%CI: 0.7-1.4]). wawomjhuzw (eknsploxgw ) View more	-	01 Jul 2017
NCT00250276 (CTgov)	Phase 3	Human Papillomavirus Infection	798	Cervarix™ (Cervarix Lot1 Group)	skelqauypn(ohprcnxugv) = jcmopnuzpl bobehpkumx (yaeuopglkj, boinmzzdyu - lrglahdzpa) View more	-	17 Mar 2017
				Cervarix™ (Cervarix Lot2 Group)	skelqauypn(ohprcnxugv) = vxpqfxhnqd bobehpkumx (yaeuopglkj, scsftwpqdt - pmnnhzfbnu) View more
NCT01462357 (NCT0146235, CTgov)	Phase 3	Human Papillomavirus Infection	1,079	Placebo+Cervarix (Cervarix 2 Dose Group)	gnysdwetbi(surpyqypqg) = mindjmfmbt xdyvnvsswi (mwphxtqksg, etbzrtwlln - svuxsdocuj) View more	-	28 Mar 2016
				Placebo+Gardasil (Gardasil 2 Dose Group)	gnysdwetbi(surpyqypqg) = hlddvtktho xdyvnvsswi (mwphxtqksg, clrtdqmdcg - avmdoalqqe) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis